SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...

The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate ...

A total of 295 eligible patients were enrolled with a median follow-up of 5.0 years. The arms were well balanced, with a median age of 65 years (IQR 59-71), 50% with positive surgical margins, 51% ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced ...

BAMF Health in Grand Rapids is offering an alternative treatment for prostate cancer that doesn't involve chemotherapy.